Journal of Clinical Pharmacy and Therapeutics最新文献

{"title":"Organoids for Drug Repurposing: A Literature Review","authors":"Ryo Okuyama","doi":"10.1155/jcpt/8827167","DOIUrl":"https://doi.org/10.1155/jcpt/8827167","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> What is Known and Objective</h3>\u0000 \u0000 <p>Drug repurposing offers a time- and cost-effective means for drug development. Accordingly, the accurate prediction of human efficacy is crucial for its success. Organoids have emerged as valuable tools for evaluating compound efficacy in three-dimensional environments closely resembling in vivo organs. However, a comprehensive overview of their application in drug repurposing is lacking. This systematic literature review discusses the origins, applications, and target diseases of organoids employed for drug repurposing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic search of original articles published up to March 5, 2025, was conducted in PubMed using the keywords “organoid” and “drug repurposing.” Trends in publications, organoid sources, research objectives, and target diseases were analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results and Discussion</h3>\u0000 \u0000 <p>Research on drug repurposing using organoids initially emerged in 2016 and has grown rapidly since the 2020s. Patient-derived tissue organoids, primarily derived from cancer tissues, are the most used. Organoids derived from pluripotent stem cells are mainly utilized for organs that are difficult to obtain from human tissues. These organoids are most frequently used for evaluation of the efficacy of repurposed drug candidates identified through other methods as well as for the primary screening of existing drug libraries, demonstrating broad utility for drug repurposing research. Most target diseases are cancers, with colorectal cancer being predominant. Organoids are anticipated to play increasingly important roles in drug repurposing, particularly for organs with limited tissue availability and complex three-dimensional structures, as well as for a diverse range of diseases beyond cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> What is New and Conclusions</h3>\u0000 \u0000 <p>This study is the first to comprehensively review the use of organoids for drug repurposing. These findings provide valuable insights for researchers pursuing drug repurposing and encourage effective integration of organoids into drug repurposing strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/8827167","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting Drug Targets in Human Cancers","authors":"David Calderón Guzmán,&nbsp;Norma Osnaya Brizuela,&nbsp;Armando Valenzuela Peraza,&nbsp;Maribel Ortiz Herrera,&nbsp;Diego E. Ortega Garcia,&nbsp;Hugo Juarez Olguin,&nbsp;Gerardo Barragán Mejía","doi":"10.1155/jcpt/4853636","DOIUrl":"https://doi.org/10.1155/jcpt/4853636","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>A large amount of knowledge has accumulated regarding the pharmacology of most cancer types, including their side effects, and during the last decade, many novel agents have emerged, accompanied by increased costs for healthcare systems.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Artificial intelligence (AI) was applied in healthcare services, and the benefit of its use in the prediction of the targets of low molecular weight compounds that can affect biological processes was assessed (proportion of the top predicted targets, common name, target class and probability).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>Designing the chemical agent or molecule chosen and the program will give the protein target prediction immediately by AI. A tuning algorithm device, with new information input in the web application interface, was used.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Information was arranged in order and fed to an in silico target prediction/Swiss TargetPrediction (STP). This tool is a computational method used to predict the most probable protein targets of small molecules, as well as to envisage what happens when many chemotherapy drugs are combined in cancer treatment. It aids in understanding some molecular processes controlling specific physical traits or biological activities to elucidate probable beneficial and adverse consequences. In addition, it helps to predict imprecision of defined molecules and pave the way to drug repositioning. Prediction is carried out employing the ligand-based drug design (LBDD), which enables comparison of the correlation between the molecule under examination and the known binding molecules of a large set of target proteins.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Target activity profiles enable a systematic repurposing process by extending the target profile of drugs, and then drug repurposing with AI provides a cost-effective strategy to reuse approved drugs for new medical indications and the availability of new treatments, reduces development costs and mitigates risks due to the cost of the cancer drug agents, coupled with high cancer disease prevalence, which means the current cost trajectory is untenable for most world healthcare systems.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/4853636","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145626367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Real-World Study of CAR-T Hematological Adverse Events Based on FAERS Database","authors":"Xiaoyue Gao,&nbsp;Fangyuan Hu,&nbsp;Yinghong Zhai,&nbsp;Lei Yuan,&nbsp;He Li,&nbsp;Xiaofei Ye,&nbsp;Zhuo Wang","doi":"10.1155/jcpt/5538794","DOIUrl":"https://doi.org/10.1155/jcpt/5538794","url":null,"abstract":"<p>Chimeric antigen receptor T-cell therapy (CAR-T) is an emerging therapy for malignancies, including refractory B-cell lymphoma, follicular lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Postmarketing monitoring is essential to ensure the rational administration of CAR-T because of its high occurrence rate of adverse events. Thus, we collected the adverse event reports from the FAERS database between the first quarter of 2017 and the second quarter of 2025. Disproportion analysis methods, including the reporting odds ratio and information component, were used to identify potential hematological AEs associated with CAR-T therapy. A total of 47,118,226 reports were analyzed, and 99,497 adverse events associated with CAR-T-cell therapy were identified. We found 11,689 hematological adverse events accounted for 11.75% of the total adverse events, of which cytopenia (ROR025 = 33.87, IC025 = 4.95), hemophagocytic lymphohistiocytosis (HLH, ROR025 = 28.20, IC025 = 4.71), and myelodysplastic syndrome (MS, ROR025 = 34.41, IC025 = 4.98) were highly underrated in the real world. All six CAR-T products were associated with hematological adverse events, and the typical hematological adverse events varied among different products. A high proportion and frequency of death outcomes were identified after CAR-T-related hematological adverse events, such as thrombocytopenia, HLH, and cytopenia. Cytokine release syndrome frequently overlapped with hematological adverse events, including cytopenia, HLH, and thrombocytopenia. Our results may help clinicians identify rare but potentially fatal hematological AEs at an early stage, effectively reducing the risk of lethal hematological toxicity of CAR-T therapy.</p>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5538794","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145618826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Safety Incidents Involving Antipsychotics: A Cross-Sectional Study Based on the Danish Patient Safety Database","authors":"Tara Hoffmann Faaborg,&nbsp;Mette Gibskov Fløe Andersen,&nbsp;Olga Alexandrovna Tchijevitch,&nbsp;Anne Estrup Olesen","doi":"10.1155/jcpt/2038343","DOIUrl":"https://doi.org/10.1155/jcpt/2038343","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction and Purpose</h3>\u0000 \u0000 <p>Antipsychotics are commonly prescribed to treat mental illnesses, with usage increasing. Although they provide therapeutic benefits, these medications can be associated with errors, e.g., wrong dosages or administration to the wrong patient. Such errors can compromise patient safety and treatment outcomes. In Denmark, healthcare professionals must report patient safety incidents (PSIs) to the Danish Patient Safety Database (DPSD). This system aims to identify high-risk situations and facilitate learning. The goal of this study was to gain detailed insights into PSIs involving antipsychotics in the Danish primary healthcare and hospital sectors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This descriptive cross-sectional study analyzed all reported moderate, severe, and fatal PSIs related to selected antipsychotics reported to the DPSD between January 2022 and December 2022. Data were categorized by two extractors using REDCap.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 7,042 PSIs were reported with 469 incidents classified as moderate, severe, or fatal. Thirty-four incidents were excluded. Quetiapine, olanzapine, and risperidone were the most frequently involved drugs (247/435, 56.8%). Most PSIs (372/435 85.5%) were of moderate severity. Errors most often occurred during administration (65.3%), with omissions, wrong dosage, and wrong-patient errors being the most common. Social housing (47.1%) and hospitals (25.5%) were the most frequently reported settings for PSIs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study highlights the need for targeted interventions to reduce medication errors and improve patient safety in both primary care and hospital settings in Denmark. Most errors occurred during administrations, and overall, the most frequent issues were omissions, incorrect dosages, and wrong-patient incidents. While PSIs related to antipsychotics remain a concern, reported severity indicates that they may not always result in significant clinical severity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/2038343","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145581383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Real-World Analysis of Adverse Events With Two Types of Single-Inhaler Triple Therapy: A VigiAccess Database Study","authors":"Baiquan Zhang,&nbsp;Jiayu Bai,&nbsp;Lu Zhou","doi":"10.1155/jcpt/6677307","DOIUrl":"https://doi.org/10.1155/jcpt/6677307","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The advent of single-inhaler triple therapies (SITTs), including fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FOR/GLY), has expanded treatment options for chronic obstructive pulmonary disease (COPD). This study explores adverse drug reactions (ADRs) related to these SITTs using data from the WHO-VigiAccess database and compares their safety profiles.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective analysis was conducted using ADR reports associated with FF/UMEC/VI and BDP/FOR/GLY from the WHO-VigiAccess database. Data included patient demographics and reported adverse events (AEs). Disproportionality analysis was performed using the reporting odds ratio (ROR) and proportional reporting ratio (PRR) to assess the association between SITTs and specific AEs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 21,539 AEs related to FF/UMEC/VI and BDP/FOR/GLY were identified in the VigiAccess database. Commonly reported ADRs included dyspnoea, cough, COPD, headache, dizziness and pneumonia. FF/UMEC/VI was more frequently associated with injuries, poisoning and procedural complications (39.46%), whereas BDP/FOR/GLY showed a higher incidence of respiratory, thoracic and mediastinal disorders (42.06%). Disproportionality analysis revealed an increased ROR (3.04) and PRR (2.76) for FF/UMEC/VI regarding injury-related events, indicating a stronger signal compared to BDP/FOR/GLY. These findings underscore the diversity of ADRs associated with SITTs and highlight the need for careful clinical monitoring. However, the voluntary nature of VigiAccess and inherent reporting biases, such as visibility and selection bias, may affect the completeness and reliability of the data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>analysis of WHO-VigiAccess reports reveals both shared and distinct ADRs between FF/UMEC/VI and BDP/FOR/GLY. Due to limitations, such as under-reporting and reporting bias inherent to spontaneous databases, these findings should be interpreted with caution. Clinicians are encouraged to tailor COPD treatment based on both efficacy and potential ADR profiles to ensure optimal and personalized care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/6677307","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145522035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Systematic Review of Traditional Uses, Phytochemistry, and Pharmacology of Chinese Herb Medicine for Schizophrenia","authors":"Sihan Zhao,&nbsp;Yonghou Zhao,&nbsp;Ming Yu,&nbsp;Jianbo Chai,&nbsp;Xinhui Yao","doi":"10.1155/jcpt/9996801","DOIUrl":"https://doi.org/10.1155/jcpt/9996801","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Ethnopharmacological Significance</h3>\u0000 \u0000 <p>Schizophrenia, a complex psychiatric disorder with multifactorial etiology, profoundly affects patients’ behavior, cognition, affect, and thought processes. Given the stagnation in novel drug development, notable treatment-related adverse effects, and suboptimal recovery rates, the identification of innovative therapeutic agents and strategies to mitigate side effects remains a critical unmet need. Preclinical advances have increasingly validated the scientific rationale for the clinical efficacy of medicinal plants. Consequently, the exploration of botanical antipsychotic agents has gained global traction due to their favorable safety profiles and emerging evidence of efficacy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective of the Review</h3>\u0000 \u0000 <p>This review synthesizes a decade of preclinical and translational research on medicinal plants and traditional ethnomedicines for schizophrenia treatment. It provides a comprehensive analysis of the pharmacology and molecular mechanisms underlying the therapeutic potential of plant-derived active ingredients, serving as a foundational resource for future drug development and clinical translation efforts.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A systematic literature review was conducted using PubMed, Web of Science, Elsevier, Scopus, SciFinder, Springer, and the China National Knowledge Infrastructure (CNKI). Search terms included “schizophrenia,” “traditional medicinal plants,” “Chinese materia medica,” “active ingredients,” and “phytochemicals.” Studies were selected based on their focus on natural products and ethnopharmacological interventions for schizophrenia published in the last decade. Following rigorous screening, data were categorized by plant-derived bioactive compounds (e.g., flavonoids, polysaccharides, and alkaloids) and their mechanisms of action.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Natural products and traditional ethnomedicines constitute promising sources for novel antipsychotic drug development. Emerging evidence supports the translational potential of integrating phytotherapeutics into clinical practice, though significant gaps persist. Future research must prioritize comprehensive pharmacokinetic/toxicological profiling, standardized clinical trials, and mechanistic elucidation of plant-derived compounds to realize their full therapeutic potential.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/9996801","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145521784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determination of the 90% Effective Dose of Remimazolam in Combination With a Low Dose of Alfentanil for Suppressing Responses During Upper Gastrointestinal Endoscopy Insertion","authors":"Pengfei Yin,&nbsp;Yifu Liang,&nbsp;Binwei Hu,&nbsp;Qing Xie,&nbsp;Mi Wang,&nbsp;Zhiying Feng,&nbsp;Xianhui Kang","doi":"10.1155/jcpt/3473867","DOIUrl":"https://doi.org/10.1155/jcpt/3473867","url":null,"abstract":"<p>Remimazolam has shown safety and efficacy in providing sedation during gastroscopy, but research on its specific clinical dosage is limited. This study aimed to determine the 90% effective dose (ED₉₀) of remimazolam when used with a low dose of alfentanil for inducing sedation in adult patients undergoing gastroscopy. Fifty adult participants underwent upper gastrointestinal (GI) endoscopy with anesthesia via intravenous boluses of remimazolam and alfentanil (4 μg/kg). The initial remimazolam dose was 0.2 mg/kg, adjusted using the biased coin up-and-down (BCUD) sequential method. The ED₉₀ of remimazolam, administered with 4 μg/kg alfentanil, was found to be 0.2375 mg/kg (95% CI: 0.1500–0.2725). Hemodynamics remained stable, with no significant adverse events and high satisfaction scores from patients, anesthesiologists, and endoscopists (4.90 ± 0.043, 4.92 ± 0.039, and 4.92 ± 0.039, respectively, on a 5-point scale). The combination of remimazolam and low-dose alfentanil is safe and effective for adult upper GI endoscopy.</p><p><b>Trial Registration:</b> Chinese Registry of Clinical Trials: ChiCTR2200062535</p>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/3473867","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145521811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interventions to Improve Standard Initiation of Long-Acting Injectable Antipsychotics in a University-Affiliated Psychiatric Hospital: A Quasiexperimental Study","authors":"Maryam Mousavi,&nbsp;Maryam Taghizadeh-Ghehi,&nbsp;Aarefeh Jafarzadeh Kohneloo,&nbsp;Zahra Mirsepassi,&nbsp;Ali-Akbar Nejatisafa","doi":"10.1155/jcpt/9093978","DOIUrl":"https://doi.org/10.1155/jcpt/9093978","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Long-acting injectable antipsychotics (LAI-APs) were recommended to improve treatment adherence and reduce recurrence rates. Initiating LAI-APs can be challenging due to complexities in dosing schedules.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>We aimed to assess the impact of multifaceted interventions on the initial dosing schedule of LAI-APs in a university-affiliated psychiatric hospital.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study consisted of three phases: first, the preintervention baseline evaluation phase, followed by guideline development and active dissemination in the hospital (guideline presentation and educational session). Second, the 1 month peri-intervention phase, in which audit and feedback were performed. The postintervention phase consisted of a 3-month evaluation. All admitted patients for whom LAI-APs were initiated were identified and studied. The concordance with institutional guidelines was determined by considering the initial dose, initial interval, and oral overlap during three phases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 101, 31, and 51 orders were evaluated in the study phases, respectively. Guideline-concordant orders increased from 2.1% in baseline to 48.4% and 64.5% before and after feedback in the peri-intervention phase, respectively, and decreased to 21.6% in the postintervention phase (<i>p</i> &lt; 0.001). Nonconcordance initial dose decreased from 83.7% at baseline to 38.7% in the second phase and reached 62% in the last phase (<i>p</i> &lt; 0.001). The frequency of LAI-AP and OAP mismatch was 67.6%, 10.5%, and 21.9% in the three study phases, respectively (<i>p</i> &lt; 0.001). The academic level of the attending physician increased the odds of an appropriate initial dose by 3.92 times. The odds of a proper initial interval were higher when the attending physician had a higher academic level (OR = 2.53, 95% CI = 1.25–5.12, <i>p</i> = 0.01) and was female (OR = 2.4, 95% CI = 1.09–5.29, <i>p</i> = 0.029).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Concordance with the institutional guideline in LAI-APs dosing improved following multifaceted interventions; however, the improvement was not sustained. Therefore, continued audit and feedback might be necessary to maintain the effects.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/9093978","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145470235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Desensitization of Immunomodulating Agent–Related Hypersensitivity Reactions as a Means to Provide Therapeutic Options in the Management of Plasma Cell Disorders (DeHyperPCD)","authors":"Jack T. Seki,&nbsp;Eshetu G. Atenafu,&nbsp;Sita Bhella,&nbsp;Christine Chen,&nbsp;Suzanne Trudel,&nbsp;Chloe Yang,&nbsp;Donna Reece,&nbsp;Jesus Giovanni Piza Rodriguez,&nbsp;Harjot Vohra,&nbsp;Ritu Kushwaha,&nbsp;Anca Prica","doi":"10.1155/jcpt/6275323","DOIUrl":"https://doi.org/10.1155/jcpt/6275323","url":null,"abstract":"<p>Hypersensitivity reactions (HSRs) can be a significant barrier to a patient’s cancer treatment journey. HSRs caused by immunomodulating agents, specifically lenalidomide (LEN) can be overwhelmingly distressful, paradoxically depriving patients of access to a clinically meaningful drug. Based on our historical clinical experiences, we have learned that the rapid desensitization protocol (RDP), when executed precisely, can enable patients to successfully resume LEN treatment. This served as the impetus for initiating our prospective study. We consecutively enrolled 10 patients diagnosed with plasma cell disease who had experienced a previous HSR specifically with LEN. After fully recovering from their initial reactions, patients underwent a controlled 10–12 steps incremental increase in drug dosage administration, followed by daily resumption of LEN over a 90-day period. All 10 (100%) patients successfully completed the protocol and continued on further LEN treatment cycles, although 1 patient voluntarily chose to withdraw from the study due to recurrent symptoms after receiving 2 doses of LEN. Three (30%) patients remained symptom-free throughout the follow-up period. Six (60%) patients experienced mild and short-lived HSR reactivation; however, all had the ability to take LEN for the majority of the study period. RDP enables patients to continue taking LEN and maintains the health-related quality of life (HR-QoL) by reducing the occurrence of HSR. RDP empowers patients to participate in future clinical trialsinvolving novel treatments that contain LEN as a backbone therapy, opportunities they would have otherwise been ineligible for.</p>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/6275323","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145469858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Different Diuretic Protocols on the Prevention of Renal Impairment and Extravasation Incidences During Short Hydration in Cisplatin Administration","authors":"Sohei Ohshima,&nbsp;Takuya Araki,&nbsp;Hideaki Yashima,&nbsp;Reiko Sakurai,&nbsp;Yohei Ohsaki,&nbsp;Akemi Tsunoda,&nbsp;Hiromi Sekine,&nbsp;Koujirou Yamamoto,&nbsp;Norifumi Tsukamoto","doi":"10.1155/jcpt/5568932","DOIUrl":"https://doi.org/10.1155/jcpt/5568932","url":null,"abstract":"<p>The short hydration method using magnesium and diuretics has been widely adopted to prevent cisplatin-induced nephrotoxicity. Both mannitol and furosemide are commonly used as diuretics in this approach, but there is no clear consensus on the benefits or risks of combining the two. Mannitol is associated with a higher risk of vascular problems, such as extravascular leakage and vasculitis, owing to its high osmolality. In this study, we investigated the risk of vascular problems and cisplatin-induced nephrotoxicity in patients who underwent short hydration with both mannitol and furosemide and in those who underwent short hydration with furosemide alone during the administration of cisplatin. Propensity score matching was performed to control for background characteristics, and logistic regression analysis was conducted to identify risk factors. The use of both mannitol and furosemide was significantly associated with a higher risk of extravasation (odds ratio [OR] = 8.29) and vascular events (OR = 12.58) compared with the use of furosemide alone. In contrast, the degree of renal function decline and incidence of grade ≥ 2 nephrotoxicity did not significantly differ between the groups. These findings suggest that adding mannitol to furosemide does not provide an additional benefit in preventing cisplatin-induced nephrotoxicity but may increase the risk of vascular adverse events. Therefore, as a general rule, furosemide alone is recommended as the diuretic in the short hydration method to prevent cisplatin-induced nephrotoxicity as well as extravascular leakage and vasculitis.</p>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5568932","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145407442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}